A Study of PF-04217903 in Patients With Advanced Cancer
A Study of PF-04217903 in Patients With Advanced Cancer
PF-04217903 may work in cancer by blocking the cell growth, migration and invasion of tumor
 cells. PF-04217903 is a new member in a class of drugs called c-Met/hepatocyte growth factor
 receptor tyrosine kinase inhibitors. This research study is the first time PF-04217903 will
 be given to patients. PF-04217903 is taken by mouth daily.
The study was prematurely discontinued due to a strategic development decision by Pfizer on
 10FEB2012. The decision to terminate was not based on any safety concerns.
Inclusion Criteria:

 -  Advanced solid tumors, histologically proven at diagnosis which is refractory to
 standard of care or for whom no standard of care therapy is available

 -  Adequate blood cell counts, normal kidney function, and performance status of 0 or 1

 Exclusion Criteria:

 -  Major surgery, radiation therapy or anti-cancer therapy within 2 weeks of starting
 study treatment

 -  Prior stem cell transplant

 -  Active or unstable cardiac disease or heart attack within 12 months of starting study
 treatment